Novartis beats sales expectations for Genmab-developed Kesimpta

Swiss Novartis has surpassed projections for multiple sclerosis treatment Kesimpta, based on Genmab’s antibody ofatumumab, in the second quarter.

Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix

Swiss pharmaceutical giant Novartis has exceeded analysts’ expectations for second-quarter sales of Kesimpta, a treatment for multiple sclerosis developed by Danish biotech firm Genmab, which receives 10% of sales in royalty payments under an existing licensing agreement.

The Swiss firm is in Q2 booking core operating income of USD 4.27bn against the forecast USD 4.2bn, based on estimates collected by Bloomberg.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs